Cancer Drug Discovery and Development Developments in T Cell Based Cancer Immunotherapies Ebook PDF
Cancer Drug Discovery and Development Developments in T Cell Based Cancer Immunotherapies Ebook PDF After decades of disappointing results resilient to extensive efforts to improve the efficacy of immunotherapy against cancer, patients and scientists are witnessing a revolution. A rapid translation of concepts from the bench to the bedside is finally making a difference in overall survival of patients with different types of cancers, including those traditionally considered non-responsive to immunotherapy. Clinical studies have proven unequivocally the effectiveness of T cell-based therapies that can induce regression of late stage cancers otherwise resistant to standard therapy. Regressions are associated with prolonged patients’ survival, achieving, in some cases, durable disease-free survival.
Cancer Drug Discovery and Development Developments in T Cell Based Cancer Immunotherapies Ebook PDF Many written accounts on large studies that validate the clinical usefulness of immunotherapy have appeared monthly in high-impact journals. This is leading to a rapid inflation of the field characterized by the rapid expansion of tumor immuno- therapy clinical programs and participation of oncologists to meetings focused on this discipline. In the last 3 years, for instance, the Society for Immunotherapy of Cancer (SITC) has more than doubled participation to its annual meeting with nearly 2000 attendees.
Cancer Drug Discovery and Development Developments in T Cell Based Cancer Immunotherapies Ebook PDF This long-awaited success is giving both clinicians and scientists new opportuni- ties. The high frequency of objective responses allows for a more efficient study of mechanisms of responsiveness and identification of biomarkers as a smaller number of patients must be accrued to observe a sufficient number of responding cases. The shortened length of time necessary to perform informative clinical studies expedites the feedback loop stimulating research based on clinical evidence while simultane- ously helping the design of second-generation clinical studies. In addition, the expansion of clinical protocols to larger patients cohorts in phase three or even post- licensing studies allows for a less fragmented approach to the understanding of human cancer biology by evaluating more homogenous patient populations in better controlled settings. This provides grounds for prospective validation of concepts developed during monitoring of early phase trials.